1. Pink Sheet
  2. >>Archive

Lilly Is Attentive To ADHD: Tomoxetine Into Phase III; 2001 NDA Planned

 
• By The Pink Sheet

Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet